Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.53 |
| ▸ | CES1 | P23141 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.52 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.51 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.51 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.51 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.51 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.51 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.51 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.51 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9217709 | 0.83 | SMN1; SMN2 (0.56) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL21117744 | 0.79 | CES2 (0.50) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL2930023 | 0.79 | CES2 (0.50) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL1742218 | 0.79 | CES2 (0.59) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL1147702 | 0.78 | KDM4E (0.73) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL4508472 | 0.78 | CES2 (0.64) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL28799522 | 0.77 | SMN1; SMN2 (0.58) | LMNAKMT2AALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL11223392 | 0.76 | CES2 (0.61) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL1422257 | 0.76 | CES2 (0.61) | CES2CES1LMNAL3MBTL1NAPRT | |
| SCHEMBL28727383 | 0.76 | CES2 (0.61) | CES2CES1LMNAL3MBTL1NAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115142148-B | High-performance binary polyacrylonitrile-based carbon fiber precursor and preparation method thereof | 东华大学 | 2023-03-21 | — | — | CN | claimed |
| CN-115142148-A | High-performance binary polyacrylonitrile-based carbon fiber precursor and preparation method thereof | 东华大学 | 2022-10-04 | — | — | CN | claimed |
| WO-2023220131-A2 | PI3Kα INHIBITORS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| CN-115142148-B | High-performance binary polyacrylonitrile-based carbon fiber precursor and preparation method thereof | 东华大学 | 2023-03-21 | — | — | CN | disclosed |
| CN-115142148-A | High-performance binary polyacrylonitrile-based carbon fiber precursor and preparation method thereof | 东华大学 | 2022-10-04 | — | — | CN | disclosed |
| EP-2091936-B1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA LP (US) | 2013-05-15 | — | — | EP | disclosed |
| US-8389549-B2 | Substituted pyridines useful for treating pain | PURDUE PHARMA L.P. (US) | 2013-03-05 | — | — | US | disclosed |
| EP-2479173-A1 | Therapeutic agents useful for treating pain | Purdue Pharma LP (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20100130552-A1 | Therapeutic Agents Useful for Treating Pain | PURDUE PHARMA L.P. | 2010-05-27 | — | — | US | disclosed |
| EP-2091936-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | Purdue Pharma LP (US) | 2009-08-26 | — | — | EP | disclosed |
| WO-2008133973-A1 | THERAPEUTIC AGENTS USEFUL FOR TREATING PAIN | PURDUE PHARMA L.P. (DE) | 2008-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130552-A1 | Therapeutic Agents Useful for Treating Pain | ARRB1, OPRK1, OPRD1 | CES2 4211/4885CES1 3217/4885LMNA 4304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.